BXP-001 Plus Radiotherapy Extends Progression-Free Survival in Advanced Tumors at ESMO 2026
Start here
At ESMO 2026 in Madrid on October 24, 2026, researchers presented phase 2/3 results from the randomized iNATURE trial, showing that BXP-001 combined with radiotherapy significantly extended progression-free survival in patients with advanced tumors. The trial was co-sponsored by Genvoy Bio/Bay Bio and the University of Hong Kong-Shenzhen Hospital, and the findings were delivered in rapid oral and poster presentations. The report also points to notable efficacy in preventing post-surgical recurrence. No specific progression-free survival figures, sample size, or hazard ratio have been disclosed so far, so quantitative outcomes await fuller publication.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickESMO 2026: BXP-001 Plus Radiotherapy Significantly Extends Progression-Free Survival in iNATURE Advanced Tumor Randomized Trial
The iNATURE trial, presented at ESMO 2026, showed that BXP-001 combined with radiotherapy significantly extended progression-free survival in a randomized controlled study of advanced tumors. The trial was co-sponsored by Genvoy Bio/Bay Bio and the University of Hong Kong-Shenzhen Hospital, with the phase 2/3 results presented as rapid oral and poster presentations in Madrid, Spain on October 24, 2026. The original report also claims notable efficacy in post-surgical recurrence prevention, but lists no specific PFS figures, sample size, or hazard ratio.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 24 16:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.